Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease
Locatelli, Franco (Contributor), Pagliara, Daria (Contributor), Locatelli, Franco (ORCID:0000-0002-7976-3654) (Creator)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 8590% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications. Pediatr Blood Cancer 2012;59:372376. (c) 2012 Wiley Periodicals, Inc
Downloadable Archival Material, English, 2012
WILEY PERIODICALS, INC, 2012